Companies similar to EPIGENETIX
Sign up to Download

1-30 of 6,250,586 results

  • www.camzyoshcp.com
  • 2
Weak CYP2C19 Inhibitors or Moderate CYP3A4 Inhibitors: Concomitant use with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor increases CAMZYOS exposure, which may increase the risk of adverse drug reactions. Initiate CAMZYOS at the recommended..
Relevance: 24.410898
  • epigenetix.com
  • 1
  • 1
  • 5
Studies with the dual BRD4 and p300/CBP inhibitor EP31670 (NEO2734) are now underway in Myelofibrosis in combination with a JAK inhibitor. We are also studying patients with other myeloid malignancies. Guided by our experience in solid tumor patients..
Relevance: 24.118235
  • www.mirati.com
  • 7
  • 3
  • 15
At Mirati, we are relentlessly focused on finding meaningful breakthroughs and targeted solutions for genetic and immunological drivers of cancer while fostering a culture of inclusion, collaboration and innovation. Watch the video below to learn..
Relevance: 21.633125
  • ruconest-conference.com
RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH)..
Relevance: 21.240797
  • www.erleadahcp.com
ERLEADA® 240 mg is the only single-tablet, once-daily, novel† androgen receptor inhibitor 1-3... ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer..
Relevance: 20.661232
  • www.zemaira.com
  • 4
  • 7
  • 2
ZEMAIRA is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated... ZEMAIRA is..
Relevance: 20.618534
  • www.opnabio.com
  • 2
  • 26
Opna Bio is a clinical stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company was founded to develop drugs aimed at disrupting the actions of an unprecedented new cancer target - fragile-X..
Relevance: 20.452656
  • orladeyohcp.com
  • 2
ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older...
Relevance: 19.910564
  • theseusrx.com
  • 3
  • 3
  • 18
Theseus Pharmaceuticals is passionately committed to improving the lives of cancer patients by working to outsmart cancer resistance. Led by a team of targeted oncology pioneers with a proven track record developing and commercializing cancer..
Relevance: 19.839697
  • oncoseer.com
  • 1
  • 1
  • 8
OncoSeer Diagnostics, Inc. (OncoSeer), a collaboration with UT Southwestern Medical Center (UTSW), is developing multimarker blood tests that diagnose and predict immune related adverse events (irAE) in oncology patients undergoing immune checkpoint..
Relevance: 19.645597
  • www.brukinsa.com
  • 1
BRUKINSA® (zanubrutinib) is a BTK Inhibitor approved for adult patients. Official BeiGene website. Learn about Brukinsa for MCL, MZL and WM... Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia and other infections..
Relevance: 19.315733
  • www.enbrelpro.com
Amgen SupportPlus provides eligible patients with financial support resources and other helpful patient support services... Learn about Enbrel® (etanercept), a TNF inhibitor, for autoimmune diseases like moderate to severe rheumatoid arthritis and..
Relevance: 18.736137
  • www.ryaltris.com
  • 2
  • 4
  • 1
RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and..
Relevance: 18.411293
  • www.bergenbio.com
  • 5
  • 1
  • 12
BerGenBio is a clinical-stage biopharmaceutical company developing bemcentinib, a selective AXL inhibitor for lung cancer... BerGenBio is leveraging its solid leadership position in understanding the role of AXL to develop a new therapeutic approach..
Relevance: 18.370298
  • www.furventexon20.com
  • 1
  • 1
Be part of developing furmonertinib, an oral, highly brain-penetrant mutation selective EGFR inhibitor for first-line patients with non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations... Ongoing Phase 1b a study showed..
Relevance: 18.362339
  • acrivon.com
  • 5
  • 32
Acrivon is developing targeted therapies to improve the lives of patients. At the frontier of proteomics, Acrivon's proprietary patient selection method is designed to profoundly alter precision oncology drug development and the treatment landscape..
Relevance: 18.34218
  • heathsciences.com
No More Cold Sores No More Cold Sores No More Cold Sores About The Viral Inhibitor Buy Now Testimonials * We respect the privacy of anonymous testimonials. Help protect their anonymity by respecting their privacy too. * MD, Orem, Utah"My wife had a..
Relevance: 18.189686
  • priovanttx.com
  • 1
  • 68
Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of..
Relevance: 18.172832
  • abcentra.com
  • 1
  • 14
At Abcentra, we are a clinical-stage biopharmaceutical company focused on bringing new and better treatment options to patients with coronary artery disease, with the aim of preventing heart attacks... Our clinical-stage product, Orticumab, is a..
Relevance: 18.089241
  • www.johnnealeltd.co.uk
  • 3
  • 2
We can now supply Inhibitor BB and Inhibitor BFF which are corrosion inhibitor packages which give benefits in bio-stability of metal working fluids. Suitable for use in synthetic and semi-synthetics... for all applications, including new technology..
Relevance: 17.871338
  • davidaskinconsulting.com
  • 1
  • 1
DXA Consulting LLC d/b/a David Askin Consulting is led by David Askin, PhD. David is a hands-on innovator and scientific leader in CMC drug development with over 30 years Biotech/Pharma experience. The great majority of David's experience was gained..
Relevance: 17.844797
  • www.impacttherapeutics.com
  • 4
  • 3
  • 9
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage responses..
Relevance: 17.571373
  • www.ayvakyt.com
  • 2
  • 1
AYVAKYT® (avapritinib) is indicated as monotherapy for the treatment of adult patients with aggressive SM (ASM), SM with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy... AYVAKYT is a..
Relevance: 17.504156
  • solirisnmosd-hcp.com
  • 2
SOLIRIS, a complement inhibitor, increases a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-..
Relevance: 17.475904
  • regranion.com
  • 2
Regranion, LLC is a clinical-stage biopharmaceutical company delivering breakthrough solutions for autoimmune skin diseases by targeting hyperinflammation... RGRN-305, our lead product, is an orally delivered potent small molecule inhibitor of heat..
Relevance: 17.430681
  • www.jiuxin.net
  • 1
  • 2
Our company's business philosophy is "first-class products, first-class service, mutual benefit, common development"... Jilin Jiuxin Industrial Group Chemical Co., Ltd. is located in Jilin City Jilin Economic and Technological Development Zone,..
Relevance: 17.38389
  • www.dayonebio.com
  • 4
  • 3
  • 15
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for patients of all ages with life-threatening diseases. Day One was founded to address a critical unmet need: the dire lack of therapeutic..
Relevance: 17.364672
  • enjaymohcp.com
  • 1
ENJAYMO, a proximal classical complement C1s inhibitor, increases susceptibility to serious infections, including those caused by encapsulated bacteria e.g. Neisseria meningitidis (any serogroup, including non-groupable strains), Streptococcus..
Relevance: 17.351345
  • www.kronosbio.com
  • 6
  • 2
  • 26
At Kronos Bio, we're focused on creating a world where no life is cut short by cancer or other serious diseases. That's why we're developing therapeutics that target the dysregulated transcription that causes cancer and autoimmune diseases-to bring..
Relevance: 17.285137
  • xatmep.com
  • 1
XATMEP® is a folate analog metabolic inhibitor indicated for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a multi-phase, combination chemotherapy maintenance regimen. XATMEP is also indicated for the..
Relevance: 17.187761